Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memory Pharmaceuticals

Criteria

Inclusion Criteria:

• standardized MMSE Score of 10 to 24 points

• diagnosis of probable Alzheimer's disease

• magnetic resonance imaging or computed tomography examination compatible with AD

• modified Hachinski Ischemia Score of less than or equal to 4

• currently receiving no AD therapy or currently receiving donepezil, rivastigmine, or galantamine

Exclusion criteria:

• head injury associated with cognitive impairment

• history of vascular dementia stroke, transient cerebral ischemic episodes, major depression, major psychotic disorder, or symptomatic postural hypotension

• treatment for Alzheimer's disease other than donepezil, rivastigmine, or galantamine; tacrine is not permitted in the last 30 days or memantine in the last 90 days

• treatment with calcium channel blockers or any investigational medications within the prior 30 days